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Abstract
Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder of
lipoprotein metabolism. Patients can be heterozygous (HeFH) with one mutated allele,
homozygous (HoFH) with two identical mutations, or compound heterozygous with
different mutations in each allele. HoFH is the more severe form of the disease and is
associated with extremely elevated levels of total cholesterol and low‐density lipopro‐
tein cholesterol  (LDL‐C).  These lipid abnormalities  are associated with accelerated
atherosclerosis and cardiovascular disease (CVD) and an increased risk of cardiac events
and early death. The prevalence of HoFH has been estimated to be 1 in 1 million;
however, this is likely an underestimation as the disease is substantially underdiag‐
nosed and undertreated. Early diagnosis and treatment are important to reduce CVD
events. Aggressive therapy with conventional agents such as statins and ezetimibe
produce  substantial  reductions  in  LDL‐C,  but  patients  rarely  reach  target  goals.
Apheresis should be considered in all  patients with HoFH, although LDL‐C levels
rapidly rebound to baseline levels. Three recently introduced novel agents (mipomers‐
en,  lomitapide,  and evolocumab)—each with a unique mechanism of action—have
increased  therapeutic  options  in  this  difficult‐to‐treat  population.  When  added  to
standard therapy, these agents produce significant additional LDL‐C lowering and can
potentially improve clinical outcomes.
Keywords: evolocumab, familial hypercholesterolemia, lomitapide, mipomersen,
treatment
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1. Introduction
Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder of lipoprotein
metabolism, usually caused by mutations in the low‐density lipoprotein (LDL) receptor (LDLR)
gene or other genes that affect LDLR function. Patients can be heterozygous (HeFH) with one
mutated allele, homozygous (HoFH) with two identical mutations, or compound heterozygous
with different mutations in each allele [1]. Patients with HoFH have either a complete absence
or marked impairment (i.e., 2–30% activity) in LDLR function [1]. There are a number of defects
in lipid metabolism among patients with FH that include reduced LDLR‐mediated catabolism
of LDL, impairment of apolipoprotein B (apo B)‐mediated clearance of LDL, and increased
proprotein convertase subtilisin/kexin type 9 (PCSK9) levels, which mediates posttranslational
destruction of LDLRs [2, 3].
Since the reduction of LDLRs in HoFH is more pronounced than that seen with HeFH,
hypercholesterolemia is usually more severe in HoFH than in HeFH and is characterized by
very high serum levels of total cholesterol and LDL‐cholesterol (LDL‐C). Levels of LDL‐C are
typically above 500 mg/dL and total cholesterol levels range from 650 to 1000 mg/dL when
HoFH is untreated, whereas LDL‐C levels are typically greater than 300 mg/dL when treated
[2–5]. High‐density lipoprotein cholesterol (HDL‐C) is often decreased and triglyceride levels
are generally normal [4].
Figure 1. Cumulative LDL exposure in patients with FH [8, 9]. Modified from Horton et al. 2009 [9].
The severe lipid abnormalities associated with HoFH result in accelerated atherosclerosis,
accelerated cardiovascular disease (CVD), and an increased risk of cardiac events and early
death. It is estimated that CVD risk is increased by up to 20‐fold in untreated patients and still
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elevated approximately 10‐fold in patients receiving statins [5–7]. The lifelong exposure of
highly elevated lipid levels means that signs/symptoms of CVD occur at an early age—
typically prior to 20 years of age and as early as preteen years with the highest risk in males
[5, 8]. Females develop CVD about 10 years later than males [6]. Young patients often have
severe and widespread atherosclerosis in all major arterial beds, including the carotid,
coronary, femoral, and iliac, and there have been instances of acute myocardial infarction and
sudden death in patients as young as 4 years of age [8]. The CVD risk is related to cumulative
LDL‐C exposure. As seen in Figure 1, patients with HoFH exceed the theoretical threshold of
LDL‐C exposure in early childhood compared with early middle age for patients with HeFH
and after age 60 years for normal healthy individuals [8, 9]. Although, as with all individuals,
the risk of developing CVD is also related to the presence of other genetic or environmental
risk factors, the effect of each risk factor is amplified in the setting of dramatically elevated
cholesterol levels [4].
The physical signs and symptoms of HoFH are characterized by accelerated atherosclerosis
and the deposition of cholesterol. Atherosclerotic manifestations include vascular endothelial
damage that produces premature coronary artery disease (CAD), peripheral artery disease,
and valvular disease (e.g., aortic stenosis) [4]. Deposition of cholesterol results in the devel‐
opment of cutaneous or tendinous xanthomas and corneal arcus [8]. Xanthomas typically occur
around the eyelids and tendons of the feet, hands, and elbows [5].
HoFH is substantially underdiagnosed and undertreated [7]. For example, it is estimated that
less than 1% of patients with FH are diagnosed in most countries and that only 48% of patients
with FH were receiving statin therapy in one Danish study [7]. Most patients with FH are not
identified because of inconsistent screening and general unawareness [6]. Indeed, the disease
is often not recognized until the initial cardiovascular (CV) event [6].
2. Epidemiology
The exact prevalence rate of HoFH is unknown. Although the prevalence is historically
estimated to be approximately 1 in 1 million [7], this likely underestimates true prevalence
rates. More recent estimates, based on surveys of unselected general populations that found a
prevalence of HeFH of 1 in ∼200 or 1 in 244, suggest a prevalence of 1 in 160,000 to 1 in 300,000
for HoFH [10]. Founder mutations that reduce genetic variation can influence the prevalence
in certain racial groups or geographic locations, resulting in increased prevalence in certain
groups (e.g., French Canadian, the Netherlands, Lebanese, Hokuriku district of Japan, South
African Afrikaners) [11–15]. National programs that include patient registries and cascade
screening have been useful for identifying patients and facilitating treatments.
3. Genetics
True HoFH is caused by two identical mutations that are inherited in an autosomal dominant
pattern [16]. Two mutant alleles of the LDLR gene (MIM 606945) cause the majority (85–95%)
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of cases [7, 10, 17]. Mutations in this gene cause a reduction in LDLR activity and are associated
with decreased clearance of LDL particles and increased LDL‐C levels.
Secondary genes associated with HoFH include APOB (MIM107730), PCSK9 (MIM 607786),
and LDLR‐adaptor protein 1 (LDLRAP1; MIM 605747) [8, 10, 17]. In addition to “true” HoFH,
patients with HoFH can have compound heterozygous mutations (different mutations in each
allele of the same gene) or double heterozygous mutations (mutations in two different genes
affecting LDLR function) [7, 10]. The severity of the HoFH depends on residual LDLR activity.
Irrespective of the underlying genetic defect, patients with HoFH are classified as either
receptor negative (i.e., <2% residual activity) or receptor defective (i.e., 2–25% residual
activity) [10]. The effect on LDL‐C concentrations is also related to genotype. Homozygous
LDLR‐defective mutations are generally associated with the highest LDL‐C levels, followed
by compound heterozygous LDLR‐defective + LDLR‐negative mutations, homozygous
LDLRAP1 or LDLR‐defective mutations, homozygous APOB or PCKS9 gain‐of‐function
mutation, and double heterozygous mutation [5, 10]. Metabolic defects include impaired LDL
uptake (the most common functional defect), hepatic oversecretion of apo B, decreased
catabolism of triglyceride‐rich lipoproteins, increased plasma levels of lipoprotein(a) (Lp(a)),
and low levels of HDL‐C [10].
4. Diagnosis
Since CV risk is related to the cumulative exposure to elevated lipids, early diagnosis is
important for earlier treatment of HoFH to reduce CV risk. Although genetic testing can
confirm FH, it is not well defined since genetic confirmation can be difficult to verify in some
patients [10]. Indeed, genetic testing is generally not needed as the disease is primarily
diagnosed via clinical and biochemical features [6–8, 10, 18]. A number of diagnostic criteria
have been proposed [8], but they are typically based on family history (i.e., HeFH in both
parents and/or premature CAD), the presence of physical manifestations (i.e., tendon xantho‐
mas, corneal arcus) at an early age, severely increased LDL‐C, and molecular diagnosis.
Patients with HoFH generally have untreated LDL‐C levels >500 mg/dL (>13 mmol/L) or
treated levels ≥300 mg/dL (≥7.76 mmol/L) [8]. However, not all patients (especially children)
with HoFH have significantly elevated LDL‐C, with more than one‐half of Dutch children with
HoFH having LDL‐C levels between 217 and 379 mg/dL (5.6–9.8 mmol/L) [10]. Patients with
a suspected diagnosis of HoFH should typically be referred to a specialized center for proper
comprehensive management [6, 10].
Since early detection of patients with HoFH is crucial for the prevention of CVD, targeted and
cascade (i.e., identifying family members at risk) screening is recommended for the identifi‐
cation of new cases in adults [6, 7, 16, 19, 20]. Targeted screening to identify index cases is
recommended for patients with hypercholesterolemia and at least one of the following
features: personal/family history of xanthomas or premature CVD or family history of
significant hypercholesterolemia or sudden premature cardiac death [6, 7]. Specific criteria in
Europe (i.e., European Atherosclerosis Society [EAS]) are similar, but somewhat different than
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those of the National Lipid Association in the United States (US), with slightly different
cholesterol cut‐points for screening [21]. Such testing is important because most patients
identified via screening were not aware of the diagnosis and were therefore not receiving
therapy [17]. The index subject should be referred for genetic screening and a family pedigree
should be created to identify potential cases, followed by cascade screening with LDL‐C
measurements [7]. Targeted screening is also recommended in children and adolescents with
CV risk factors [6, 16]. Prenatal diagnosis is possible, and it is recommended that the partners
of known cases of HeFH should be tested to exclude the disease [22]. Economic modeling has
shown that comprehensive screening using cholesterol and DNA testing is cost‐effective [19].
5. Treatment options
Given the severity of hypercholesterolemia with increased CV risk, HoFH requires intensive
therapy. However, HoFH is often unresponsive to traditional treatment [20]. A number of
societies and associations in the United States (American College of Cardiology/American
Heart Association; National Lipid Association) [20, 23, 24], Europe (EAS; National Institute for
Health and Care Excellence) [10, 25], and Canada (Canadian Cardiovascular Society) [6] have
published guidelines on the treatment of HoFH. The primary target of treatment in these
guidelines is the reduction of LDL‐C via a combination of lifestyle, antihyperlipidemic
pharmacotherapy, and apheresis [6, 10, 20, 23, 26]. Since lipid‐lowering therapy is associated
with a delayed onset of CVD and prolonged survival, early and aggressive therapy should be
initiated as soon as possible [6, 10]. The EAS has recommended LDL‐C targets of <100 mg/dL
(<2.5 mmol/L) in children and <70 mg/dL (<1.8 mmol/L) in adults [10].
Statins, the first line of pharmacotherapy to lowering cholesterol level, effectively lower LDL‐
C 10% to 25% in patients with HoFH [10, 26], and even more (approximately 50% reduction
of LDL‐C) in those with HeFH [26]. The combination with ezetimibe (acholesterol absorption
inhibitor) leads to additive 15–20% LDL‐C reductions [6, 10]. Other agents such as bile acid
sequestrants, niacin, fibrates, and probucol can be considered. A clinical study of HoFH
patients from South Africa found that statin use was associated with a 51% reduction in the
risk of major CV events and a 66% reduction in the risk of death although the mean LDL‐C
levels in the patients were only reduced 26% [27].
Because of very high LDL‐C levels in HoFH, its target level is extremely difficult to achieve
though cholesterol has been reduced [10]. The inability of standard lipid‐lowering therapies
to produce the necessary effect is further exacerbated by the fact that these agents work by
increasing expression of LDLRs. Thus, lipoprotein apheresis should be considered in all
patients with HoFH and should be initiated early. For example, the EAS guidelines recommend
that apheresis should ideally be initiated by age 5 and not later than age 8 in children with
HoFH [10]. Canadian guidelines recommend apheresis in adults with HoFH with LDL‐C >329
mg/dL (>8.5 mmol/L) and in children (weighing >15 kg or >7 years of age) with an LDL‐C >193
mg/dL (>5 mmol/L) [6]. LDL apheresis selectively removes LDL‐C without affecting immu‐
noglobulins or other proteins with reductions of approximately 60% [18]. However, a rapid
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rebound in LDL‐C is seen with levels returning to baseline within 2 to 4 weeks [18, 20].
Although there are no randomized trials evaluating the effect of apheresis on clinical outcomes,
there is clinical evidence that apheresis can contribute to regression and/or stabilization of
atherosclerotic plaque [10]. Limitations to the use of apheresis include lack of availability in
some locations, high cost, long procedure duration, and the need to maintain vascular access
[4]. It is recommended that patients on apheresis undergo routine monitoring to assess carotid
atherosclerosis (carotid ultrasound), progression of aortic valve/root disease (echocardiogra‐
phy), and progression of coronary atherosclerosis (stress exercise test) [6].
6. New pharmacologic therapies
Recently, three novel agents have become available—mipomersen, lomitapide, and evolocu‐
mab—each with a unique mechanism of action. Two of these agents (mipomersen and
lomitapide) target very low‐density lipoprotein (VLDL) production, while the other (evolo‐
cumab) causes increased catabolism of LDL‐C via LDLR recycling (Figure 2) [10].
Figure 2. Mechanisms of action of mipomersen, lomitapide, and evolocumab. Modified from Cuchel et al. 2014 [10].
Properties of these agents are summarized in Table 1 [28–32] and are discussed in detail in the
following sections. These agents produce additive LDL‐C lowering when combined with other
lipid‐lowering therapies such as statins, ezetimibe, and apheresis [10] and represent promising
approaches to the treatment of HoFH for those patients who cannot achieve LDL‐C targets
with conventional therapy.
Cholesterol Lowering Therapies and Drugs64
Agent MOA Indication Dosage and administration LDL‐C
lowering
Adverse events
Mipomersen29 Oligonucleotide
inhibitor of
apolipoprotein B‐
100 synthesis 
Adjunctive
therapy in
HoFH 
HoFH: 200 mg SC once
weekly 
25%  Increased transaminases
Hepatic steatosis
Injection‐site reactions 
Lomitapide
28,30,31 
Microsomal
triglyceride transfer
protein inhibitor
Adjunctive
therapy in
HoFH
HoFH: Initiate at 5 mg/day,
titrating to max of 60 mg/
day 
46% Increased transaminases
Hepatic steatosis
Evolocumab32 PCSK9 inhibitor Adjunctive
therapy in
HeFH and
HoFH
HeFH: 140 mg SC every 2
weeks or 420 mg SC once
monthlyb
HoFH: 420 mg SC once
monthly 
23% Nasopharyngitis, upper
respiratory tract
infection, influenza, back
pain, and injection‐site
reactions
aBased on phase III trials in HoFH;
bAdministered as three injections consecutively within 30 minutes.
HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL‐C, low‐
density lipoprotein cholesterol; MOA, mechanisms of action; PCSK9, proprotein convertase subtilisin/kexin type 9; SC,
subcutaneous.
Table 1. Novel agents for the treatment of HoFH.
6.1. Mipomersen
6.1.1. Pharmacodynamics
Apo B is the primary protein of VLDL, intermediate density lipoprotein, and LDL and is
essential for the production and catabolism of VLDL and LDL [33, 34]. Apo B is involved in
the packaging and distribution of both dietary and endogenously produced cholesterol and
triglycerides by lipoproteins [35]. The atherosclerotic potential of apo B is evidenced by the
observation that apo B concentrations are highly predictive for atherosclerotic disease,
including patients with FH [8, 33].
Mipomersen is an antisense oligonucleotide against the mRNA of apo B‐100, the primary
ligand for the LDLR [33, 34]. The drug reduces apo B mRNA translation, and thereby the
synthesis of apo B by ribosomes, resulting in a reduction in the secretion of VLDL. Thus,
mipomersen targets the production of LDL rather than its clearance (Figure 2) [34]. In animal
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models, species‐specific inhibition of antisense apo B leads to reductions in apo B‐100, LDL‐
C, and total cholesterol in a dose‐ and time‐dependent manner [29, 35].
Mipomersen is readily absorbed after subcutaneous administration with the highest drug
concentrations in the liver and kidney. Bioavailability ranges from 54% to 78% over a dose
range of 50 to 400 mg [29]. Elimination is primarily via metabolism by endonucleases and renal
excretion (as parent drug and metabolites) and the half‐life ranges from 1 to 2 months [29, 35].
In the United States, mipomersen is indicated as an adjunct to lipid‐lowering medications and
diet to reduce LDL‐C, apo B, total cholesterol, and non‐HDL‐C in patients with HoFH [36].
The drug is administered once weekly by subcutaneous injection [29].
6.1.2. Efficacy
Based on its mechanism of action and its demonstrated activity in patients with hypercholes‐
terolemia as either monotherapy or in combinations, it is reasonable that mipomersen would
be effective in the treatment of HoFH [35]. In a phase II, open‐label, study, mipomersen was
administered in a dose‐escalation fashion (50, 100, 200, and 300 mg) to nine patients with
HoFH. Patients received five doses over 2 weeks followed by weekly dosing through week 6
(n = 5) or week 13 (n = 4). At week 6, LDL‐C reductions ranged from 0.5% to 36%. By week 13,
the reductions ranged from 9.0% to 51.1%[29].
The phase III trial of mipomersen in patients with HoFH included 51 patients with clinical
diagnosis or genetically confirmed HoFH [37]. Mean baseline LDL‐C was 402 mg/dL (10.4
mmol/L). Patients who received maximally tolerated doses of lipid‐lowering drug were
randomized to receive mipomersen 200 mg subcutaneously (n = 34) or placebo (n = 17) once
weekly for 26 weeks [37]. The primary endpoint was the percent change in LDL‐C concentra‐
tion from baseline. Secondary endpoints were changes from baseline in apo B, total cholesterol,
and non‐HDL‐C concentrations. At 26 weeks, mipomersen‐treated patients achieved signifi‐
cant reductions in all primary and secondary endpoints versus placebo: LDL‐C (–24.7%), apo
B (–26.8%), total cholesterol (–21.2%), and non‐HDLC (–24.5%). By comparison, reductions for
those in the placebo group were: LDL‐C (–3.3%), apo B (–2.5%), total cholesterol (–2.0%), and
non‐HDL‐C (–2.9%). In addition, mipomersen was also associated with substantial reductions
in Lp(a) (–31.1%), triglycerides (–17.4%), and VLDL (–17.4%), and a significant increase in
HDL‐C (+15.1%). Notably, there was substantial variability in the reduction of LDL‐C concen‐
trations among HoFH patients receiving mipomersen with values ranging from +2% to –82%.
The magnitude of treatment effect was independent of baseline LDL‐C, age, race, or sex in
multivariate analysis [37].
6.1.3. Safety/tolerability
In the phase III HoFH trial, the most common adverse events among patients with HoFH were
injection‐site reactions (76%), flu‐like symptoms (29%), nausea (18%), headache (15%), and
chest pain (12%). Injection‐site reactions included erythema (56%), hematoma (35%), pain
(35%), pruritus (29%), discoloration (29%), macule (15%), papule (12%), and swelling (12%).
Similar rates of injection‐site reactions were observed in pooled data from other clinical trials
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with rates of 84% and 33%, respectively, for those in the mipomersen and placebo groups [29].
Most reactions were of mild to moderate severity with only 5% discontinuing treatment
because of an injection‐site reaction. In pooled phase III trials that included all patients with
hypercholesterolemia, 30% of patients experienced flu‐like symptoms (e.g., pyrexia, chills,
myalgia, arthralgia, malaise, fatigue) compared with 16% of those receiving placebo [29].
Laboratory abnormalities in the phase III HoFH trial were primarily characterized by elevated
liver transaminases. Alanine aminotransferase (ALT) increases of ≥1 but ≤3 times the upper
limit of normal (ULN) were observed in 50% of patients in the mipomersen groups but was
similar to that seen with placebo (53%). However, increased ALT of ≥3 × ULN was seen in 12%
of mipomersen‐treated patients but none of the placebo‐treated patients [37]. In the pooled
phase III trials, 8.4% of patients receiving mipomersen experienced an elevated ALT >3 × ULN
on two consecutive occasions at least 7 days apart compared to 0.0% of placebo‐treated
patients [29]. These ALT changes were generally associated with lesser elevations of aspartate
aminotransferase (AST). Mipomersen was also associated with an increase in hepatic fat in
9.6% of patients compared with 0.02% of placebo‐treated patients. However, this increase was
not accompanied by changes in patient weight, plasma glucose, or HbA1c, suggesting that
there is no associated increased risk of metabolic syndrome. It is suggested that the hepatic
steatosis and elevated transaminase concentrations are inherent consequences of attenuating
apo B production. Nevertheless, mipomersen carries a black box warning for the risk of
hepatotoxicity (i.e., increased transaminases and hepatic steatosis) and the drug is only
available in the United States via a Risk Evaluation and Mitigation Strategy program [29].
6.2. Lomitapide
6.2.1. Pharmacodynamics
The microsomal triglyceride transfer protein (MTP) is an intracellular lipid‐transfer protein
located in the lumen of the endoplasmic reticulum. It is responsible for binding and moving
individual lipid molecules between membranes. MTP is a major mediator of the assembly and
secretion of apo B‐containing lipoproteins such as VLDL from the liver, which is converted
into LDL‐C, and chylomicrons, which contain dietary cholesterol and triglycerides, from the
intestine [30, 31, 38]. The rare genetic condition abetalipoproteinemia provides insight into the
importance of MTP in lipid handling and transport. Abetalipoproteinemia is characterized by
loss‐of‐function mutations in the gene encoding MTP (i.e., MTTP) and is associated with
marked hypocholesterolemia and an absence of apo B‐containing lipoproteins in the plasma
[35]. Lack of functional MTP in abetalipoproteinemia results in the inability to load apo B with
lipoproteins and the targeted proteasomal degradation of apo B. This leads to a loss of intestinal
secretion of chylomicrons and liver secretion of VLDL and a consequent lack of LDL‐C in the
plasma [35]. Thus, inhibition of MTP is a potentially powerful therapeutic target to reduce the
production of apo B‐containing lipoproteins, particularly VLDL (the precursor of LDL‐C) [30].
Lomitapide is a small molecule that inhibits MTP action. By binding directly to MTP, lomita‐
pide inhibits the synthesis of triglyceride‐rich chylomicrons in the intestine and VLDL in the
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liver, with a resulting reduction in plasma LDL‐C [39]. The mechanism of action of lomitapide
in inhibiting MTP is illustrated in Figure 2.
Oral absorption of lomitapide is poor with an absolute bioavailability of 7%, thought to be due
to a first‐pass effect. Lomitapide pharmacokinetics is approximately dose proportional after
single oral doses of 10–100 mg. The drug is extensively metabolized in the liver and has a
terminal half‐life of 39.7 hours [28, 30]. Lomitapide is indicated in the United States and the
European Union as an adjunct to a low‐fat diet and other lipid‐lowering treatments, including
LDL apheresis where available, to reduce LDL‐C, total cholesterol, apo B, and non‐HDL‐C in
patients with HoFH [28, 39].
6.2.2. Efficacy
An initial study in 18 patients with HoFH evaluated the addition of lomitapide to usual lipid‐
lowering therapy, including apheresis [40]. The dose of lomitapide was gradually titrated
during the first 14–18 weeks to a target dose of 60 mg/day (80 mg/day if LDL and safety criteria
were met). The mean overall LDL‐C reduction was 44% at 6 months compared with baseline
but the individual values ranged from an increase in LDL‐C of 19% to a reduction of 93%,
indicating a wide variability of effect. Four patients achieved an LDL‐C <100 mg/dL (<2.6
mmol/L) and another two achieved levels <170 mg/dL (<4.4 mmol/L) [40].
The pivotal phase III open‐label trial included 29 patients with HoFH based on clinical criteria
or documented genetic mutations [41]. Upon enrollment, patients were required to enter a 6‐
week run‐in phase in which patients were initiated on concomitant lipid‐lowering therapy
(including apheresis), vitamin E, essential fatty acids, and a low‐fat diet. Patients then entered
a 26‐week efficacy phase where lomitapide was initiated at 5 mg/day and titrated (at 4‐week
intervals) up to a maximum of 60 mg/day. Following the efficacy phase, patients continued
lomitapide therapy in a 52‐week safety phase. Mean baseline total cholesterol and LDL‐C levels
were 429 mg/dL (11.1 mmol/L) and 336 mg/dL (8.7 mmol/L), respectively [41]. Twenty‐three
of 29 patients completed both the efficacy phase (26 weeks) and safety phase (52 weeks). At
the end of 26 weeks, patients achieved statistically significant mean reductions from baseline
in total cholesterol (–46%; P < 0.0001) and LDL‐C (–50%; P < 0.0001) [41]. The large majority of
patients (n = 19/23 [83%]) achieved LDL‐C reductions >25% and one‐half (n = 12/23) had a >50%
reduction [41]. Furthermore, 8 patients achieved LDL‐C concentrations <100 mg/dL (<2.6
mmol/L). Based on these LDL‐C reductions, three patients permanently discontinued aphe‐
resis and three permanently increased the time interval between apheresis treatments.
Significant reductions from baseline were also seen for VLDL cholesterol (–45%), non‐HDL‐C
(–50%), triglycerides (–45%), and apo B (–49%). Lipid lowering was independent of the use of
apheresis, suggesting that apheresis does not affect the lipid‐lowering efficacy of lomitapide
[42]. These reductions were maintained throughout the 52‐week safety phase with reductions
of 35% and 38%, respectively, for total cholesterol and LDL‐C despite changes in concomitant
lipid‐lowering therapy [41]. Nineteen of the 23 patients who competed the efficacy and safety
phases entered a long‐term extension study [43, 44]. As of 2015, the median duration of
treatment was 5.1 years [43]. At 126 weeks, mean LDL‐C levels were reduced by 46%. Similar
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reductions were also observed in apo B (–54%), non‐HDL‐C (–47%), VLDL cholesterol (–37%),
and triglycerides (–38%) [43, 44].
Additional evidence of the efficacy of lomitapide in HoFH comes from a Japanese trial [45]
and the Lomitapide Observational Worldwide Evaluation Registry (LOWER) [45, 46]. The
Japanese trial included nine patients with a mean baseline LDL‐C of 199 mg/dL (5.2 mmol/L),
which was reduced to 118 mg/dL (3.1 mmol/L) at week 26 (–42%) [45]. Significant reductions
were also seen for total cholesterol (–32%), non‐HDL‐C (–40%), VLDL (–42%), apo B (–45%),
and triglycerides (–42%) [45]. LOWER is a noninterventional registry open to lomitapide‐
treated patients that is designed to evaluate the long‐term safety and efficacy of lomitapide in
clinical practice and is eventually expected to enroll at least 300 patients and follow them for
at least 10 years [47]. As of March 2015, 84 patients had enrolled in LOWER, with all but one
from the United States [46]. Titration of lomitapide occurred slower than in the pivotal phase
III trial, with a mean dose of 10 mg reached only after 12 months. The mean reduction in LDL‐
C at month 4 was 42%, with 38% of patients achieving a reduction of at least 50% at 6 months
[46, 47].
6.2.3. Safety/tolerability
Oral lomitapide was generally well tolerated in patients with HoFH. Although the majority of
patients experienced an adverse event in the phase III trial (n = 27/29 [93%] in the efficacy phase;
n = 21/23 [91%] in the safety phase), most events were mild to moderate in intensity [41]. The
most common adverse events were gastrointestinal in nature, with 27/29 patients in the efficacy
phase and 21/23 patients in the safety phase experiencing a gastrointestinal event [41]. The
most common events in the phase III trial were gastrointestinal in nature (27 patients during
the efficacy phase and 17 during the safety phase), most commonly manifested as diarrhea,
nausea, dyspepsia, and vomiting [41, 43]. Three patients discontinued treatment due to a
gastrointestinal event [41]. The incidence of gastrointestinal events decreased during the
extension phase: diarrhea (42%), nausea (32%), vomiting (26%), and dyspepsia (11%) [43].
Ten patients in the phase III trial had elevated levels of ALT, AST, or both >3 × ULN at least
once during the trial, and four patients had elevations at least 5 × ULN [41]. No patient
discontinued treatment permanently because of these elevations and all were managed by
either dose reduction or temporary interruption of lomitapide [41, 43]. In the LOWER registry,
elevated transaminase levels ≥3 × ULN were observed in only 16 patients (19%) [46].
Among the 20 patients from the phase III trials with evaluable nuclear magnetic resonance
spectroscopy data, hepatic fat increased from 1% at baseline to 8.6% at the end of week 26 and
8.3% at week 78 [41]. Hepatic fat continued to increase through the extension trial [43], although
the accumulation of fat appears to be reversible after discontinuation of lomitapide [39].
Whether this fat accumulation is a risk factor for the development of steatohepatitis and
cirrhosis is currently unknown. No cases of cirrhosis or late‐stage liver disease have been
identified in the long‐term extension studies [43].
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6.3. Evolocumab
6.3.1. Pharmacodynamics
PCSK9 is a key regulator of LDLR function. When PCSK9 binds to the LDLR, LDLR degrada‐
tion is enhanced in the liver, thereby increasing LDL‐C plasma concentrations [4].Although
some patients with HoFH have no LDLR function, up to 75% have residual activity (between
2% and 25%) [2]. Patients with HoFH also have increased PCSK9 function. Among patients
with residual LDLR function, PCSK9 inhibition may be useful for lowering LDL‐C [2].
Evolocumab is a human immunoglobulin G2 monoclonal antibody directed against human
PCSK9. By binding to PCSK9, evolocumab inhibits circulating PCSK9 from binding to the
LDLR, preventing PCSK9‐mediated LDLR degradation and permitting LDLR to recycle back
to the liver cell surface. This increases the number of LDLRs available to clear LDL from the
blood, thereby lowering LDL‐C level (Figure 2) [32, 48, 49].
6.3.2. Efficacy
The addition of evolocumab to stable lipid‐lowering therapy was evaluated in an open‐label
pilot trial in eight patients with LDLR‐negative or LDLR‐defective HoFH [32]. Patients received
subcutaneous evolocumab 420 mg every 4 weeks for 12 weeks, maintained for an additional
12 weeks at 4‐week intervals, and then 420 mg of evolocumab every 2 weeks for an additional
12 weeks [32]. All eight patients had LDLR mutations, with six patients having defective
receptor status (i.e., residual LDLR function) and two having negative LDLR function. Mean
baseline LDL‐C was 441 mg/dL (11.4 mmol/L) [32]. After 12 weeks of every 4‐week dosing,
mean LDL‐C decreased by a mean of 17% (range, +5% to –44%). The two patients with negative
LDLR activity did not achieve reductions in LDL‐C [32]. After 12 weeks of every 2‐week dosing,
mean LDL‐C was reduced by 14%, again with no reductions in the two patients that were
LDLR‐negative. Apo B was reduced by 14.9% and 12.5% by the 4‐week and 2‐week dosing
schedules and Lp(a) was reduced by 11.7% and 18.6%, respectively, by the two schedules.
However, there was little change in triglycerides, HDL‐C, or apolipoprotein A1 with either
schedule [32].
The pivotal randomized, phase III, double‐blind, placebo‐controlled trial included 49 patients
with HoFH on stable lipid‐lowering therapy (but not apheresis) for at least 4 weeks. Patients
were randomized in a 2:1 ratio to receive evolocumab 420 mg or placebo every 4 weeks [48].
LDLR mutations in both alleles were present in 45 of 48 patients (94%), with 22 of these having
the same mutation in both alleles (true HoFH) and 23 having different mutations in each LDLR
allele (i.e., compound heterozygous FH) [48]. One patient receiving evolocumab had LDLR
receptor‐negative mutations in both alleles and another had autosomal recessive hypercho‐
lesterolemia. The mean decrease in ultracentrifugation LDL‐C was 23.1% for those receiving
evolocumab compared with a 7.9% increase for the placebo group (primary endpoint) [48].
Evolocumab was also associated with a 19.2% reduction in apo B at week 12, although changes
in Lp(a), HDL‐C, and triglycerides were not significantly different relative to placebo [48].
Response to evolocumab correlated with the underlying genetic cause of HoFH, with a greater
reduction in LDL‐C among those with two LDLR‐defective mutations than in those with even
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a single LDLR‐negative mutation. However, among the 20 patients receiving evolocumab who
had defects in either one or both alleles, a 29.5% reduction in ultracentrifugation LDL‐C was
achieved [48]. The patient with LDLR‐negative mutations in both alleles and the one with
autosomal recessive hypercholesterolemia did not respond to evolocumab (LDL‐C levels
increased by 3–10%) [48].
The efficacy of evolocumab in combination with apheresis is under evaluation in the Trial
Assessing Long Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders
(TAUSSIG) in patients with severe FH not controlled with current lipid therapy [50]. Patients
received evolocumab 420 mg and apheresis every 2 weeks. An interim analysis found that
evolocumab was associated with a mean reduction of 17% in LDL‐C at week 12 (n = 24) and
20% at week 24 (n = 12) [50]. Four patients were able to stop or decrease the frequency of
apheresis. The three patients with LDLR‐negative mutations in both alleles did not respond
to evolocumab. Evolocumab is indicated in the United States and EU as an adjunct to diet and
other LDL‐lowering therapies for the treatment of patients with HoFH who require additional
lowering of LDL‐C.
6.3.3. Safety/tolerability
In the phase III trial in patients with HoFH, the most common adverse events among those
receiving evolocumab were upper respiratory tract infection (9%), influenza (9%),
gastroenteritis (6%), nasopharyngitis (6%), and increased ALT or AST ≥3 × ULN [48]. There
were no adverse event‐related treatment discontinuations. These rates of adverse events are
generally consistent with those seen in other large randomized trials evaluating evolocumab
in the treatment of hypercholesterolemia [49]. Immunogenicity appears to be uncommon, with
only 0.1% of patients in pooled clinical trials testing positive for binding antibody
development. There was no evidence of neutralizing antibodies and no evidence that the
presence of antidrug antibodies impacted the pharmacokinetic profile, clinical response, or
safety of evolocumab [49].
7. Conclusions
HoFH is a rare disease that is underdiagnosed and undertreated and is associated with
substantial morbidity and mortality. Early diagnosis and aggressive therapy are the corner‐
stones of the management of HoFH. Until recently, therapeutic options were limited and
insufficient to get patients to their treatment goals. The availability of novel pharmacologic
agents provides clinicians with additional treatment options in this difficult‐to‐treat popula‐
tion. Figure 3 summarizes the suggested treatment algorithm of the EAS for patients with
HoFH [10].
This algorithm highlights the novel treatment options that will allow greater reductions in
lipid levels in HoFH patients and let them achieve their target goals. It is hoped and expected
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that these expanded options will ultimately translate into improvements in clinical outcomes
including a decrease in CV events and CVD‐related mortality.
Figure 3. European Atherosclerosis Society treatment algorithm for the management of HoFH. Modified from Cuchel
et al. 2014 [10].
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